Cam Garrity, MBA’s Post

𝗣𝗵𝗮𝗿𝗺𝗮 𝟰.𝟬 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟮. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The report offers a thorough examination of the development of the Pharma 4.0 industry chain, encompassing the market landscape of the Pharmaceutical Industry (Cloud, On-premise) and IoT Industry (Cloud, On-premise), alongside profiles of key enterprises in both developed and emerging markets. It delves into cutting-edge technology, patents, emerging applications, and market trends within Pharma 4.0. Regionally, the report scrutinizes key regions such as North America, Europe, and Asia-Pacific, with North America and Europe experiencing steady growth fueled by government initiatives and heightened consumer awareness, while Asia-Pacific, notably China, leads the global Pharma 4.0 market due to robust domestic demand, supportive policies, and a strong manufacturing base. Overall, it provides a holistic understanding of the Pharma 4.0 market, offering insights into market dynamics, trends, challenges, and opportunities for stakeholders. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗣𝗵𝗮𝗿𝗺𝗮 𝟰.𝟬 𝗠𝗮𝗿𝗸𝗲𝘁.𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/dpuvzsKP *𝗕𝘆 𝗧𝘆𝗽𝗲: Cloud,  On-premise *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Pharmaceutical Industry,  IoT Industry,  Medical Equipment Industry,  Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Pfizer Inc,  Abbott Laboratories,  GE HealthCare,  Boston Scientific,  Medtronic Plc.,  Lonza Group AG,  GlaxoSmithKline plc.,  Koninklijke Philips N.V.,  Glatt GmbH,  Vertex,  Johnson & Johnson,  Goodly Innovations,  QbDVision #pharma4.0market #pharmaceuticalindustry #pharmatech #digitalpharma #pharmainnovation #pharmacare #pharmaceuticals #healthcaretechnology #pharmatechnology #industry40 #smartmanufacturing #biotech #pharmaresearch #healthcareindustry #medicine #drugdevelopment #pharmaceuticalmanufacturing #healthtech #biopharma #clinicaltrials #medicaltechnology

𝗚𝗹𝗼𝗯𝗮𝗹 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐂𝐨𝐧𝐭𝐢𝐧𝐮𝐨𝐮𝐬 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 (𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐) The global pharmaceutical continuous manufacturing market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 10.1% during 2024-2032. The rising demand for effective medicine production systems, the improvements in the pharmaceutical sector, the increasing research and development (R&D) activities, and the escalating health concerns are some of the factors propelling the market. 𝐆𝐫𝐚𝐛 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/e-VhJ9KZ 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬: ● 𝐒𝐦𝐚𝐫𝐭 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 & 𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲: The integration of IoT, AI, and ML allows predictive maintenance, adaptive control, and data-driven decisions, boosting efficiency and product quality in continuous manufacturing. ● 𝐌𝐨𝐝𝐮𝐥𝐚𝐫 & 𝐅𝐥𝐞𝐱𝐢𝐛𝐥𝐞 𝐒𝐲𝐬𝐭𝐞𝐦𝐬: The trend towards modular and flexible systems enables customization and reconfiguration for different products and production scales. This agility benefits pharmaceutical companies by optimizing processes, speeding up new drug launches, and adapting to market shifts. ● 𝐅𝐚𝐬𝐭𝐞𝐫 𝐓𝐢𝐦𝐞-𝐭𝐨-𝐌𝐚𝐫𝐤𝐞𝐭 & 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞: The flexibility of Industry 4.0 in continuous manufacturing allows pharma companies to reduce time-to-market for new drugs, giving them a competitive edge. 𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐒𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐂𝐨𝐧𝐭𝐢𝐧𝐮𝐨𝐮𝐬 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲: Baker Perkins Coperion GmbH (Hillenbrand Inc.) Eli Lilly and Company GEA Group Aktiengesellschaft Glatt Group KORSCH AG Novartis Siemens SK biotek Ireland an SK pharmteco company Thermo Fisher Scientific. Viatris 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/eqZBMZYG #pharmaceuticalcontinuousmanufacturing #pharmaceuticalcontinuousmanufacturingmarket #marketresearch #business #marketanalysis #markettrends #researchreport #marketreport #marketforecast #marketgrowth #imarcgroup #businessgrowth #investmentopportunity #industryanalysis

Explore the latest thought leadership article by Hari Kiran Chereddi, CEO of HRV Global LifeSciences and New Horizon Global Pharma, about the pharmaceutical potential of the #Global South, published by Tunisia’s Albiaanews: “The Global South should make use of the tools of the Fourth Industrial Revolution (4IR) to unleash its pharma potential.” Learn more about how AI, drones, telemedicine, and virtual supply chain support, can lift the healthcare and pharmaceutical industrie of the emerging markets spreading from East Asia to Latin America to the next level: https://lnkd.in/eH3wTzXz #NHGPharma #GlobalPharma #Pharmaceuticals #Pharma #IndianPharma #Pharmaceuticals #API #APIs #APImanufacturing #APISourcing #Businesspartnership #Pharmaindustry #DrugDevelopment #Pharmaexcellence #Business #NicheAPI #OrphanAPI #OrhanDrugs #cGMP #DrugDevelopment #Pharmaexcellence #AI #IOT #4IR #technology #smarttech #tech #pharmatech

The pharmaceutical industry has long relied on documents to share knowledge and advance drug development. But in today's digital age, that approach is both outdated and inefficient. So, I think it's high time we transition from document-centric to data-centric drug development. In this approach, companies extract and structure data from documents, building an integrated digital knowledge base. The key information within documents then becomes findable, accessible, interoperable and reusable (FAIR), and the documents themselves become an afterthought. How can companies enact this transition? A 3-step approach: 1. Index document content, not just documents themselves. 2. Use an example, like a Quality Target Product Profile, to see how this works in practice. A "Digital QTPP" aligns with ICH Q8 guidelines but shifts collaboration to data, not documents. 3. Build a data culture. Provide training and incentives to help teams adopt new tools and ways of working. Curious? Come and see me discuss this live at Making Pharmaceuticals UK on the 23rd of April. Full details here: https://buff.ly/492822I #pharma #biotech #manufacturing #data #digital #ai #technology #digitaltransformation #software #IoT #automation #information #knowledgemanagement #drugdevelopment #implementation #IT #OT #PLM #dataintegrity

Let's explore some of the ways that IoTM is changing the pharmaceutical sector: 1. Personalized medicine: IoTM devices can be used to collect data from patients that can be used to develop personalized treatment plans. 2. Enhanced patient care: IoTM devices can be used to monitor patients' health remotely, track medication adherence, and provide real-time feedback to healthcare providers. This can help to improve patient outcomes and reduce the cost of care. 3. New drug development and clinical trials: IoTM devices can be used to collect data from patients in clinical trials in real time. This data can be used to accelerate drug development and improve the success rate of clinical trials. 4. Reduced costs and improved efficiency: IoTM can be used to automate tasks in pharmaceutical manufacturing and distribution, which can help reduce costs and improve efficiency. 5. Improved supply chain visibility and traceability: IoT sensors can be attached to pharmaceutical products to track their location, temperature, and humidity in real time. This data can be used to optimize shipping routes, prevent spoilage, and ensure that products are delivered in good condition. We should anticipate seeing even more cutting-edge uses for IoT technology in the years to come as it develops. #sentropharma #pharmaceuticals #iotm #transformingpharma #PersonalizedMedicine #DrugDevelopment #SupplyChainSolutions #PharmaceuticalDistributor #pharmaceutical #pharma #pharmacy #pharmacist #medicine #pharmaceuticals #healthcare #pharmacology

Explore the latest thought leadership article by Hari Kiran Chereddi, CEO of HRV Global LifeSciences and New Horizon Global Pharma, about the pharmaceutical potential of the #Global South, published by Tunisia’s Albiaanews: “The Global South should make use of the tools of the Fourth Industrial Revolution (4IR) to unleash its pharma potential.” Learn more about how AI, drones, telemedicine, and virtual supply chain support, can lift the healthcare and pharmaceutical industrie of the emerging markets spreading from East Asia to Latin America to the next level: https://lnkd.in/eH3wTzXz #HRVGlobal #GlobalPharma #Pharmaceuticals #Pharma #IndianPharma #Pharmaceuticals #API #APIs #APImanufacturing #APISourcing #Businesspartnership #Pharmaindustry #DrugDevelopment #Pharmaexcellence #Business #NicheAPI #OrphanAPI #OrhanDrugs #cGMP #DrugDevelopment #Pharmaexcellence #Qualityassurance #AI #IOT #4IR #technology #smarttech #tech #pharmatech

𝐃𝐨 𝐲𝐨𝐮 𝐭𝐡𝐢𝐧𝐤 𝐝𝐢𝐠𝐢𝐭𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚 𝐢𝐬 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭? We think it is! Read on to learn why 👇 The pharmaceutical industry is facing challenges such as rising costs and stringent regulatory requirements. Furthermore, the 𝐚𝐠𝐢𝐧𝐠 𝐩𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧, 𝐞𝐱𝐩𝐚𝐧𝐝𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐚𝐜𝐜𝐞𝐬𝐬, and growing demands for 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 are creating a pressing need for change in the industry. To address these challenges effectively digitalization is key and embracing the potential of digital tools becomes paramount 🔧 Follow this link to get all the insights on digitalization in pharma: https://hubs.li/Q02sm_P50 For any inquiries please feel free to contact Mikael or Sonny. #PPSnordic #Digitalization #Pharma #ArtificialIntelligence #MachineLearning #BigDataAnalytics

Pharmaceutical companies in Asia are proactively adopting Industry 4.0 Digital Transformation initiatives to ensure GMP compliance and attain superior business outcomes. While several organizations have commenced this journey, a significant number are yet to embark on this critical path.   A World Pharma Today report sheds light on IDC’s findings, underscoring how the region’s pharmaceutical industry can elevate operational efficiency by embracing digital technologies. ✔ Molecule Discovery: Precision data management supports the identification, cataloguing, and simulation of drug compounds, optimizing therapeutic and commercial potential. ✔ Data-driven R&D: Collaborative platforms and data-derived insights streamline R&D operations, boosting effectiveness, reducing costs, and expediting GTM timelines. ✔Implement a Digital Roadmap: Formulating and implementing a comprehensive digital transformation roadmap, alongside expert partners, ensures robust compliance, and continuous improvement. Leading Asian pharma companies invest in long-term strategic planning, aligning digital transformation initiatives with overarching business objectives to secure sustained growth. One example of a pharmaceutical company in Asia leveraging Industry 4.0 technologies is Takeda. It implemented a smart factory concept, leveraging technologies such as AI, ML and IoT to optimize its production processes, enhance quality control, and reduce costs. The company integrated these technologies into its manufacturing execution systems, which enabled real-time monitoring, data-driven decision-making, and predictive maintenance. As articulated by Dr. Yinan Zhang, former manager of Data Analytics at Takeda, “The goal is to use a machine-learning system with an advanced algorithm that can let you know which vials are defective with a high degree of accuracy.” By incorporating elements of new products & services innovation alongside effective engagement and execution, pharma leaders in Asia are not only augmenting operational efficiency but also establishing new benchmarks in the global pharmaceutical industry.    #Pharma #DigitalTransformation #HealthcareInnovation #Asia #LifeSciences 

Future Trends in Pharmaceutical Manufacturing: What to Expect 🌍 The pharmaceutical manufacturing industry, valued at $1.6 trillion in 2023, is undergoing significant changes driven by technological advancements and the demand for more efficient production methods. Automation and AI are increasingly being integrated into manufacturing processes, enhancing precision and reducing errors. Additionally, the shift towards personalised medicine is pushing the industry to adapt with more flexible and customisable production methods, enabling the creation of tailored treatments on a smaller scale. 🌟 Sustainability is also becoming a priority, with companies adopting greener practices to reduce environmental impact. Continuous manufacturing is gaining momentum for its ability to improve efficiency by allowing uninterrupted production, while digital technologies like IoT and big data are enhancing real-time monitoring and quality control. These trends are setting the stage for a more agile, sustainable, and tech-driven future in pharmaceutical manufacturing. 🌱 At Hanley, we're excited about the pharmaceutical manufacturing industry's shift towards automation, AI, and personalised medicine. With a focus on sustainability and continuous manufacturing, these trends are driving efficiency and precision in the $1.6 trillion sector, aligning with our interest in tech-driven advancements in life sciences.#Pharmaceuticals #Manufacturing #TechInnovation #Sustainability #HanleyAutomation